Effects of Enzymatically Modified Isoquercitrin in Supplementary Protein Powder on Athlete Body Composition: A Randomized, Placebo-Controlled, Double-Blind Trial

Naomi Omi, Hideki Shiba, Eisaku Nishimura, Sakuka Tsukamoto, Hiroko Maruki-Uchida, Masaya Oda, Minoru Morita

J Int Soc Sports Nutr. 2019 Sep 10;16(1):39.

PMID: 31500646

Abstract:

Background:




Enzymatically modified isoquercitrin (EMIQ), a water-soluble quercetin, has been shown to intensify muscle hypertrophy in mice. We investigated the effect of EMIQ in supplementary protein powder on athlete body composition.













Methods:




Forty Japanese males who played American football (age: 19.8 ± 1.4 years; body height: 174.1 ± 6.0 cm; body mass: 75.5 ± 10.7 kg) were assigned to a randomized, placebo-controlled, double-blind trial of parallel group. Participants received either EMIQ in whey protein (EW, n = 19) or contrast whey protein (W, n = 20) 6 days per week over 4 months. Body composition was assessed using dual-energy X-ray absorptiometry. Markers of oxidative stress, derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP), were assessed using a free radical analytical system. Data were analyzed using a univariate and repeated measures general model statistics.













Results:




After 4 months, changes in lower limb fat-free mass and muscle mass were significantly greater in the EW group than in the W group (mean change ±95% CI; W: 324.1 ± 284.3, EW: 950.3 ± 473.2, p = 0.031, W: 255.7 ± 288.6, EW: 930.9 ± 471.5, p = 0.021, respectively). Moreover, the EW group exhibited a significantly higher BAP/d-ROMs ratio, antioxidation index, than the W group after 4 months (mean change ± SD; W: 8.8 ± 1.1, EW: 10.3 ± 2.8; p = 0.028). No significant differences in body mass, lean body mass, fat mass, or lower limb fat mass were observed between the groups.













Conclusion:




Ingestion of EMIQ in supplementary protein powder for 4 months exerts antioxidant effects and increases muscle mass among American football players.













Trial registration:




University Hospital Medical Information Network Clinical Trial Registry, UMIN000036036 . Retrospectively registered in 2019.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP482359-A	Isoquercitrin		482-35-9	Price